


BIOBANKING TO INNOVATION

Koh Furuta¹, Hiroki Nakae², Kazuhiko Okano³, Shin-ichiro Fujii⁴, Koichiro Yuji⁵, Yoshihito Nakajima⁶, Junko Ikeda², Hiroyuki Kobayashi⁷, Naoko Shobayashi², Tatsuaki Tsuruyama⁸, Hiroyuki Uchiyama⁹, Yasunari Yamanaka¹⁰

- 1. Kanagawa Cancer Center Hospital, Yokohama, Japan. 2. Japan Multiplex bio-Analysis Consortium, Tokyo, Japan. 3. ACTmed Co., Ltd., Tokyo, Japan.
- 4. Bio-Medical Standards Group, National Metrology Institute of Japan National Institute of Advanced Industrial Science and Technology, Tsukuba, Japan. 5. Project Division of International Advanced Medical Research, Institute of Medical Science, the University of Tokyo, Tokyo, Japan. 6. LPD Marketing Manager, Thermo Fisher Scientific Japan, Tokyo, Japan. 7. Axcelead Drug Discovery Partners, Inc., Fuijisawa, Japan. 8. Department of Drug and Discovery Medicine, Pathology Division, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 9. Nissui Pharmaceutical Co. Ltd., Tokyo, Japan. 10. RIKEN, Tsukuba, Japan


REPRODUCIBILITY

Reproducibility is the key to the precision medicine: no matter how the methods of clinical trials change, reproducibility is the basis of reliability of end-products (Drugs & IVDs).




With/without biobanking, reproducibility must be always guaranteed for the stakeholders & patients who get benefit from drugs & IVDs.


BACKGROUND



CIBER'S BASIC PRINCIPLES



CIBER NETWORKS



CIBER PROSPECTUS

The direction of the current medical services in the world is towards the precision medicine based on the genomic medicine. One of the infrastructures of this environment is the storage and/or utilization of bioresources including data. At this point in time, discussions regarding standardization are started in the ISO framework. Some criticized that standardization is negative to progress in technologies. History tells us, however, in some situation standardization may be positive to innovation if direction of standardization is properly placed.

We can say that discussions shall be driven by users of biorepositories, not by providers. History indicates us again that innovations are with users of technologies. Although the precision medicine seems promising, some critics point out that the precision medicine may produce medical divide. One solution to these inputs could be to set up the opened framework of biological and environmental repositories. Considering the roles of biological and environmental repositories, it is urgent for the current generation to prepare and maintain this framework in a sustainable way.

Along with declining birthrate and the following population aging, it is easily assumed that public funds may not afford to provide supports to all the social infrastructures. Under these circumstances, users of biological and environmental repositories as private partners are expected to participate to this framework in a proactive and pre-competitive manner.

We, mainly users of biological and environmental repositories, decided to network horizontally and further set up a corporation of "Council for Industrial use of Biological and Environmental Repositories (CIBER)" to commit to support a part of roles of medical infrastructure under international standards. Goal of a corporation of "Council for Industrial use of Biological and Environmental Repositories (CIBER)" is to support the social infrastructure without medical divide not only to ourselves but also to our next generations.

2018, January 22 Founders

CONCLUSIONS

The non-profit organization, CIBER, based in Tokyo Japan focuses on:

- i. to introduce the standardization systems to guarantee the reproducible results for biobank stakeholders & patients.
- ii. to facilitate setting up business models to meet the needs of biobank users/customers.
- iii. to facilitate applying internationally common platforms, standardized methods, and best practices.
- iv. to facilitate setting up conformity assessment eco system including self-assessment, contract, and/or certification/ accreditation.
- v. to facilitate innovations in the biotechnology field.

